Are Medical Stocks Lagging Arcellx (ACLX) This Year?
Here is how Arcellx, Inc. (ACLX) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Zacks Investment Research4/27/2026Negative
ACLX
Arcellx IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.73B
P/E Ratio
—
EPS
$-4.07
Beta
0.25
52W High
$115.13
52W Low
$47.86
50-Day MA
$110.81
200-Day MA
$83.72
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
61.73
PEG Ratio
—
About Arcellx Inc
Arcellx, Inc., a clinical-stage biotechnology company, is engaged in the development of various immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland.
Fundamentals
| Revenue (TTM) | $22.29M |
| Gross Profit (TTM) | $-135.32M |
| EBITDA | $-246.40M |
| Operating Margin | -3850.00% |
| Return on Equity | -53.40% |
| Return on Assets | -24.00% |
| Revenue/Share (TTM) | $0.40 |
| Book Value | $6.95 |
| Price-to-Book | 16.73 |
| Price-to-Sales (TTM) | 302.04 |
| EV/Revenue | 284.21 |
| EV/EBITDA | -6.52 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -89.20% |
| Shares Outstanding | $58.51M |
| Float | $42.96M |
| % Insiders | 11.67% |
| % Institutions | 90.33% |
Analyst Ratings
Consensus ($112.20 target)
18
HoldLatest News
More HEALTHCARE Stocks
Data last updated: 5/2/2026